Menu

The Scientist Staff

Infographic: How to Predict If a Species Is At Risk

To calculate the likelihood that organisms will be harmed by climate change, researchers estimate their exposure, sensitivity, and ability to adapt to new conditions.

Jul 1, 2018
Catherine Offord

Researchers use various methods to estimate a species’ vulnerability to climate change. One popular class of assessments takes a trait-based approach, calculating organisms’ vulnerability on the basis of their exposure to climate change, their sensitivity to that change, and their potential to adapt to new conditions, termed their adaptive capacity.

Sensitivity

A measure of how likely a species is to experience negative effects of climate change. Failing to account for traits that confer higher sensitivity can result in overoptimistic estimates of species’ vulnerability.

Adaptive Capacity

The potential for species and populations to temporarily escape the negative effects of climate change via natural selection or individual plasticity.

Exposure

The magnitude and type of environmental changes that a population is likely to experience under future climate scenarios. Estimates of exposure are strongly affected by the choice of climate forecast model, and add a considerable source of uncertainty into climate change vulnerability assessments.

Read the full story.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!